To mark the first anniversary of the Affordable Care Act this week, Health Policy Hub will be cross posting blogs from our state partners that show how people in their states are benefitting from the law. This blog was originally posted on the Pennsylvani

In a sort of Capitol call-and-response, the powerful Senate Judiciary Committee pledged to take up legislation to combat counterfeit medicines as Sen. Michael Bennet pledged to expand his own bill, the Drug Safety and Accountability Act, and seek bipartis

The Department of Justice, upon the request of Judge Roger Vinson, filed a request for an expedited appeal to the Eleventh circuit last Tuesday. This, in exchange for a clear issuing of a ‘stay’ from the Judge that requires states to continue implementati

In his keynote address to the “After Heparin” convening today, FDA Principal Deputy Commissioner John Taylor said the agency has not made enough progress in transforming its oversight system, but that bills before the last Congress—the Bennet and Dingell

The growth in the cost of health insurance premiums is one of the major drivers of escalating consumer health care costs. During the national reform process, state advocates urged the federal government to strengthen the regulations governing the rate rev

Can current safeguards in our medicine supply prevent another heparin crisis, and how do we confront quality problems so extensive that the government must seize factories because of the risk to public health? On Monday and Tuesday Mar. 14-15, the Pew Hea

Despite a heightened awareness of the need for transparency of financial relationships in clinical medicine and research, a new review of meta-analyses in JAMA found that among a sample of high-impact publications, very few of the reviews acknowledged ind

What’s behind the President’s embrace of state flexibility? President Obama surprised a lot of people, including, apparently, Congressional Democrats, when he came out in favor of moving up the date when states could seek “global waivers” under the Afford

More than half of all domestic drug manufacturing plants inspected by the FDA failed inspection last year, a new analysis by Bloomberg revealed. Looking at almost 10,000 inspection records from the last 10 years, the report shows that inspection failures